Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network, breaks down the causes of the ongoing cancer drug shortage, as well as its impact on clinical trials.
Primary causes of the cancer drug shortage include manufacturing issues, supply chain disruptions, and regulatory delays, says Crystal S. Denlinger, MD, FACP, CEO of the National Comprehensive Cancer Network (NCCN).
Recently, the NCCN released a survey of best practices for drug shortage management.
Transcript
What are the primary causes of the current cancer drug shortage, and are there any specific trends or events that have exacerbated the situation?
This is a great question, and I think that the current cancer drug shortage is actually just an extension of a drug shortage that's been going on for a while across different generic medications. The causes are primarily related to supply chain issues, and a supply chain that has little redundancy or elastic capacity, with poor incentives in the market to make these drugs. So, we have few suppliers. When a supplier goes down, or when there's an issue with a particular supplier, there's not a lot of other opportunities for other suppliers to step in.
In addition, we have to acknowledge the fact that the markets for generic drugs and the markets for brand name drugs are completely different. In the brand name drug market, we normally have high list prices, and there is incentive to make those drugs. In the generic market, it's essentially a race to the bottom, which does ultimately potentially impact sustainability and quality. The incentives to produce generic drugs are really not as strong because there is market pressure for lower and lower cost. Ultimately, you hit a threshold below which you aren't going to be able to have a steady supply of these medications, and that's where some of these drug shortages come into play.
How are the current drug shortages impacting clinical trials, particularly in terms of enrollment, budgeting, and treatment protocols?
For most clinical trials, especially the larger randomized phase 3 trials, the trial will include some form of a current standard of care backbone plus a new drug. Many of the current standard of care backbone regimens involve these generic drugs like carboplatin or 5-fluorouracil. When these drugs are in shortage, that can affect clinical trials in a number of ways. In our survey of our member institutions, 43% of the responding institutions indicated that there was some impact on clinical trials because of drug shortages. One way that it was impacted was in the potential for reduction in enrollments to clinical trials that were already open and ongoing, to make sure that the patients who were going to enroll on the trial were able to get the therapy that was required by the protocol.
We've also seen reports that centers have reduced or delayed the opening of trials that they knew had a drug that was on shortage, so that they could ensure that there was in fact enough supply for the drug that was on the protocol.
Finally, we saw greater administrative burden in opening clinical trials because of the need for procurement challenges or ways to ensure that the drugs were available in order to proceed with protocol-directed therapy.
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen